GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » E10

XTL Biopharmaceuticals (XTL Biopharmaceuticals) E10 : $-0.50 (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

XTL Biopharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was $-0.065. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.50 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average E10 Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of XTL Biopharmaceuticals was 48.50% per year. The lowest was 12.60% per year. And the median was 36.30% per year.

As of today (2024-04-27), XTL Biopharmaceuticals's current stock price is $2.422. XTL Biopharmaceuticals's E10 for the quarter that ended in Sep. 2023 was $-0.50. XTL Biopharmaceuticals's Shiller PE Ratio of today is .


XTL Biopharmaceuticals E10 Historical Data

The historical data trend for XTL Biopharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals E10 Chart

XTL Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 -0.82 -0.93 -0.97 -0.59

XTL Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -0.59 -0.62 -0.53 -0.50

Competitive Comparison of XTL Biopharmaceuticals's E10

For the Biotechnology subindustry, XTL Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Shiller PE Ratio falls into.



XTL Biopharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XTL Biopharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.065/129.8595*129.8595
=-0.065

Current CPI (Sep. 2023) = 129.8595.

XTL Biopharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201312 -0.500 98.326 -0.660
201403 -0.300 99.695 -0.391
201406 -0.200 100.560 -0.258
201409 -0.300 100.428 -0.388
201412 -0.300 99.070 -0.393
201503 -0.500 99.621 -0.652
201506 -0.100 100.684 -0.129
201509 -0.200 100.392 -0.259
201512 -0.900 99.792 -1.171
201603 -0.200 100.470 -0.259
201606 -0.200 101.688 -0.255
201609 -0.100 101.861 -0.127
201612 -0.400 101.863 -0.510
201703 -0.300 102.862 -0.379
201706 -0.270 103.349 -0.339
201709 0.400 104.136 0.499
201712 0.000 104.011 0.000
201803 0.400 105.290 0.493
201806 -0.200 106.317 -0.244
201809 0.200 106.507 0.244
201812 0.300 105.998 0.368
201903 0.800 107.251 0.969
201906 -0.600 108.070 -0.721
201909 -0.246 108.329 -0.295
201912 -0.102 108.420 -0.122
202003 0.034 108.902 0.041
202006 -0.200 108.767 -0.239
202009 -0.200 109.815 -0.237
202012 -0.200 109.897 -0.236
202103 0.100 111.754 0.116
202106 -0.200 114.631 -0.227
202109 -0.100 115.734 -0.112
202112 0.371 117.630 0.410
202203 0.093 121.301 0.100
202206 -0.100 125.017 -0.104
202209 -0.141 125.227 -0.146
202212 -0.100 125.222 -0.104
202303 -0.169 127.348 -0.172
202306 -0.067 128.729 -0.068
202309 -0.065 129.860 -0.065

Add all the adjusted EPS together and divide 10 will get our e10.


XTL Biopharmaceuticals  (NAS:XTLB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


XTL Biopharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989